Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia.

Expert review of hematology·2025

Same author

Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.

Leukemia & lymphoma·2024

Same author

The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review.

Health and quality of life outcomes·2024

Same author

Corrigendum: Drug-related problems among transfusion-dependent thalassemia patients: a real-world evidence study.

Frontiers in pharmacology·2023

Same author

Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia.

Archives of osteoporosis·2023

Same author

Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.

Journal of medical economics·2023

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study.

Shu Chuen Li¹, Sanjay Kumar Aggarwal

¹School of Biomedical Science and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia. Shuchuen.li@newcastle.edu.au

Journal of Medical Economics

|May 6, 2011

Summary

Valproate treatment for bipolar disorder resulted in significant healthcare cost savings compared to lithium. This economic evaluation found valproate to be a more cost-effective option, reducing financial burdens for patients and the healthcare system.

Related Experiment Videos

Last Updated: Jun 2, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Area of Science:

Pharmacoeconomics
Psychiatry
Health Economics

Background:

Bipolar I disorder is a chronic mental health condition requiring long-term management.
Lithium and valproate are established treatments for bipolar disorder, but their economic impact differs.
Resource utilization and associated costs are critical factors in treatment selection.

Purpose of the Study:

To compare the healthcare resource utilization between lithium and valproate in patients with bipolar I disorder.
To evaluate the economic implications of using valproate versus lithium from a healthcare system perspective.

Main Methods:

A modeled economic study was conducted alongside the international, randomized, open-label VALID study.
Health resource utilization data were collected via standardized questionnaires from patients in both treatment groups.
Cost analysis was performed based on differences in hospital visits, outpatient visits, and work days lost.

Main Results:

Efficacy and tolerability of valproate and lithium were comparable.
The valproate group showed lower utilization of hospital visits, outpatient visits, and fewer work days lost.
Modelled analysis estimated total cost savings of US$199,322, translating to US$1444 per patient or US$6278 per patient per year with valproate.

Conclusions:

Valproate use is associated with substantial cost savings for the healthcare system compared to lithium.
Choosing valproate over lithium can reduce the financial burden on patients and healthcare providers.
Economic considerations should be integrated into treatment decisions for bipolar disorder.